Healthcare / Drug Manufacturers - Specialty & GenericNSE
$89.07
+0.16 (+0.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $144.7M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
8.4x
↓EV/EBITDA
3.2x
↓ROE
11.7%
↑Gross Margin
58.2%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2026 · 4 años de histórico normalizado
Revenue CAGR
+8.7%
FCF CAGR
+34.6%
FCF margin
14.0%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.04B · net income $131.1M · FCF $144.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $1.04B | $1.04B | $1.01B | $951.1M | $951.0M | $742.0M |
| Net Income | $131.1M | $131.1M | $133.6M | $145.0M | $113.3M | $92.1M |
| EBITDA | $211.3M | $211.3M | $216.5M | $229.5M | $183.1M | $163.6M |
| EPS | — | — | 10.86 | 11.78 | 9.21 | 7.49 |
| Gross Margin | 58.2% | 58.2% | 62.2% | 38.1% | 30.2% | 32.8% |
| Operating Margin | 13.0% | 13.0% | 15.7% | 21.2% | 15.3% | 17.1% |
| Net Margin | 12.6% | 12.6% | 13.2% | 15.2% | 11.9% | 12.4% |
| Balance Sheet | ||||||
| Current Ratio | 4.68 | 4.68 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $144.7M | $144.7M | $149.3M | $141.7M | $57.4M | $44.1M |
| Returns | ||||||
| ROE | 11.7% | 11.7% | 13.5% | 16.9% | 15.9% | 15.4% |
| Valuation | ||||||
| P/E | 8.36 | 8.36 | 8.96 | 19.62 | 15.88 | 22.64 |
| EV/EBITDA | 3.21 | 3.21 | 4.26 | 10.79 | 8.61 | 11.76 |
| P/B | 0.98 | 0.98 | 1.21 | 3.32 | 2.53 | 3.48 |
| Growth & Yield | ||||||
| Revenue Growth | 2.7% | 2.7% | 6.2% | 0.0% | — | — |
| EPS Growth | — | — | -7.8% | 27.9% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.9%
Start / end P/E
n/dx → n/dx
EPS bridge
10.86 → n/d
Residual
-13.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.